Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer
The ProMisE classifier uses three tests, mismatch repair and p53 immunohistochemistry plus POLE sequencing, to sort endometrial cancers into four molecular groups that reproduce the Cancer Genome Atlas subtypes and predict outcome.
Overview
Confirmation study in 319 endometrial cancers of the Proactive Molecular Risk Classifier for Endometrial Cancer, assigning tumours to POLE-mutated, mismatch repair-deficient, p53-abnormal or p53 wild-type (no specific molecular profile) groups using immunohistochemistry and targeted sequencing.
The classifier was reproducible, could be applied to biopsy material and stratified survival, with POLE tumours faring best and p53-abnormal worst, independent of traditional risk factors.
- Four molecular groups with distinct survival; p53-abnormal worst, POLE best.
- Classifier reproducible on diagnostic biopsies with high concordance to hysterectomy specimens.
Molecular classification of every endometrial cancer, now embedded in the WHO classification and the ESGO/ESTRO/ESP guideline, rests on ProMisE; it decides adjuvant therapy and identifies candidates for immunotherapy.
- Tumours with more than one classifying feature (multiple classifiers) need hierarchical assignment rules.
- POLE sequencing is not yet universally available.
Similar pages
not linked directly; found by shared links- Key paperMolecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer.
- Key paperIntegrated genomic characterisation of endometrial carcinoma (The Cancer Genome Atlas)
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
- Key paperESGO/ESTRO/ESP guidelines for the management of endometrial carcinoma (2021)
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- TermHysterectomy
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer, Endometrial cancer with no specific molecular profile.
- Key paperNRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer with no specific molecular profile.
- TrialPORTEC-2
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.
- TermEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Mismatch-repair-deficient endometrial cancer, Endometrial cancer with no specific molecular profile.
- TrialFIRES & SENTOR (sentinel node mapping)
Shares POLE-ultramutated endometrial cancer, Endometrial cancer with no specific molecular profile.